The Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation organisation have recently requested that the US Trade Representative place the EU on its watch list for the 2018 Special 301 Report, a yearly review of the global state of intellectual property rights enforcement.
The watch list identifies trading partners engaging in harmful practices in terms of IP protection and market access for US companies.
This is an extremely worrisome development, against which the EPWG on Innovation, Access to Medicines and Poverty related diseases must take a stance, at a time when the EU is reviewing its IP incentives regime, which we support.
Nessa Childers MEP
The European Union has a major impact on access to medicines for developing countries, through its policies, legislation and bilateral and regional trade agreements. It is vital that the EU adopts appropriate measures that improve access to existing medical tools (medicines, diagnostics, vaccines) and that stimulate the research and development (R&D) of urgently-needed better tools for people in developing countries, notably for poverty-related diseases such as HIV/AIDS, tuberculosis and malaria. The Working Group operates as a Bureau of MEPs, with one Chair and four Co-Chairs, and a Secretariat, formed by Médecins Sans Frontières’ Campaign for Access to Essential Medicines and Global Health Advocates. The Working Group is open to MEPs, academics, representatives from the European Commission, international organisations and civil society.